Top 5 Stocks to Buy Now
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free OBD Stock Alerts

Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics logo
GBX 0.17 +0.01 (+3.64%)
As of 06/19/2026 11:40 AM Eastern
Compare

OBD vs. COS, C4XD, DDDD, IMM, and OKYO

Should you buy Oxford BioDynamics stock or one of its competitors? MarketBeat compares Oxford BioDynamics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford BioDynamics include Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), ImmuPharma (IMM), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry.

How does Oxford BioDynamics compare to Collagen Solutions plc (COS.L)?

Oxford BioDynamics (LON:OBD) and Collagen Solutions plc (COS.L) (LON:COS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Collagen Solutions plc (COS.L) has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. Collagen Solutions plc (COS.L)'s return on equity of 0.00% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
Collagen Solutions plc (COS.L) N/A N/A N/A

25.4% of Oxford BioDynamics shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Collagen Solutions plc (COS.L) has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M6.70-£103.52M-£0.80N/A
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled Collagen Solutions plc (COS.L)'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
Collagen Solutions plc (COS.L) Neutral

Summary

Collagen Solutions plc (COS.L) beats Oxford BioDynamics on 4 of the 7 factors compared between the two stocks.

How does Oxford BioDynamics compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 25.4% of Oxford BioDynamics shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

C4X Discovery has a net margin of 42.81% compared to Oxford BioDynamics' net margin of -1,018.54%. C4X Discovery's return on equity of 55.38% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

C4X Discovery has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Oxford BioDynamics£1.10M6.70-£103.52M-£0.80N/A

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Oxford BioDynamics Neutral

C4X Discovery has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Summary

C4X Discovery beats Oxford BioDynamics on 9 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to 4D pharma?

4D pharma (LON:DDDD) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

4D pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. 4D pharma's return on equity of -89.48% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

26.8% of 4D pharma shares are held by institutional investors. Comparatively, 25.4% of Oxford BioDynamics shares are held by institutional investors. 12.2% of 4D pharma shares are held by insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

4D pharma has higher earnings, but lower revenue than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Oxford BioDynamics£1.10M6.70-£103.52M-£0.80N/A

In the previous week, 4D pharma's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Oxford BioDynamics Neutral

4D pharma has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

4D pharma beats Oxford BioDynamics on 6 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to ImmuPharma?

Oxford BioDynamics (LON:OBD) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Oxford BioDynamics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.004, meaning that its stock price is 200% more volatile than the broader market.

25.4% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 15.6% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 6.5% of ImmuPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to Oxford BioDynamics' net margin of -1,018.54%. Oxford BioDynamics' return on equity of -316.67% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-1,018.54% -316.67% -56.23%
ImmuPharma 3,519.56%-1,397.44%-43.00%

In the previous week, Oxford BioDynamics' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.

Company Overall Sentiment
Oxford BioDynamics Neutral
ImmuPharma Neutral

ImmuPharma has lower revenue, but higher earnings than Oxford BioDynamics. ImmuPharma is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.10M6.70-£103.52M-£0.80N/A
ImmuPharmaN/AN/A-£2.51M-£0.37N/A

Summary

Oxford BioDynamics and ImmuPharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Oxford BioDynamics compare to OKYO Pharma?

OKYO Pharma (LON:OKYO) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

OKYO Pharma has higher earnings, but lower revenue than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OKYO PharmaN/AN/A-£6.70M-£0.01N/A
Oxford BioDynamics£1.10M6.70-£103.52M-£0.80N/A

OKYO Pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,018.54%. Oxford BioDynamics' return on equity of -316.67% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
OKYO PharmaN/A -397.13% -154.72%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
OKYO Pharma Neutral
Oxford BioDynamics Neutral

25.4% of Oxford BioDynamics shares are held by institutional investors. 31.9% of OKYO Pharma shares are held by company insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

OKYO Pharma has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

Oxford BioDynamics beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.

Get Oxford BioDynamics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBD vs. The Competition

Export
MetricOxford BioDynamicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£7.34M£381.57M£6.42B£2.88B
Dividend YieldN/A3.86%2.68%6.15%
P/E Ratio-0.213.1224.78366.85
Price / Sales6.706,861.77553.9186,444.11
Price / Cash3.9813.1345.0727.85
Price / Book0.2192.2610.808.01
Net Income-£103.52M-£96.07M£3.57B£5.89B
7 Day Performance-5.52%0.88%0.72%0.07%
1 Month Performance-12.76%-0.66%0.41%0.93%
1 Year Performance-53.66%54.58%29.34%72.13%

Oxford BioDynamics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBD
Oxford BioDynamics
N/AGBX 0.17
+3.6%		N/A-53.7%£7.34M£1.10MN/A45
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718KN/A106
IMM
ImmuPharma
N/AGBX 4.81
+5.4%		N/A+77.3%£30.01MN/AN/A13

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBD) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel